A Dedham, Massachusetts man says he woke up one Saturday morning, noticed a small speck in his eye, and within two weeks lost his sight in both eyes for good.
Story Snapshot
- Ed Gillen of Dedham says he went completely blind in both eyes after roughly a year on a GLP-1 drug.
- Doctors diagnosed him with non-arteritic anterior ischemic optic neuropathy (NAION), a condition tied to irreversible vision loss.
- He is now part of a lawsuit against Novo Nordisk, claiming the company failed to warn patients about the risk.
- More than 130 similar cases are already combined before a federal judge in Philadelphia.
A Speck In The Eye Turned Into Total Darkness
Gillen told Boston 25 News his vision trouble started small. He noticed what looked like a speck in one eye on a Saturday morning. Within two weeks, that minor irritation turned into complete blindness in both eyes. He described the moment plainly, saying it felt like someone flipped a switch and the lights went out for good.
Gillen had been taking a GLP-1 medication for about a year before his symptoms began. By May 2025, doctors diagnosed him with NAION, a condition that damages the optic nerve and often leads to permanent vision loss. Gillen said his doctor told him directly that his symptoms lined up with known effects tied to GLP-1 drugs like Ozempic.
Legal Claims Now Stretch Across The Country
Gillen’s story is not sitting alone. He has joined a lawsuit alleging that Novo Nordisk failed to warn patients and doctors that GLP-1 drugs could cause serious optic nerve damage and blindness. His case adds to a growing wave of litigation already working through the courts, with a multidistrict lawsuit involving more than 130 similar claims now sitting before a judge in Philadelphia.
These lawsuits center on the same rare condition, NAION, sometimes called an eye stroke because it happens when blood flow to the optic nerve suddenly drops. The condition typically strikes one eye, though doctors say there’s roughly a 15 percent chance the second eye is affected within five years. Losing vision in both eyes, as Gillen describes, remains rare even within this already uncommon diagnosis.
What Researchers Have Found So Far
The science behind these claims is still developing, and that’s worth understanding plainly, not with suspicion, just with clear eyes. A 2024 study published in JAMA Ophthalmology found that patients with type 2 diabetes who took semaglutide-based drugs faced a notably higher risk of developing NAION compared to those not using GLP-1 medications. A separate large-scale study of 37 million adults found a modest increase in NAION risk among semaglutide users compared to people taking a different class of diabetes drugs.
Other research paints a more mixed picture. A meta-analysis covering 69 randomized controlled trials found no cases of NAION in the majority of those trials. The American Academy of Ophthalmology has said the current data does not show a consistent overall increase in NAION risk, while also calling for more research. That gap between individual patient stories and population-level statistics is exactly why cases like Gillen’s carry weight even as the broader science keeps evolving.
OZEMPIC BLINDNESS? Is it really worth it?
‘Boom, lights out’: Massachusetts man shares sudden blindness journey after taking GLP-1’https://t.co/Z8PZd7JWZU via @YouTube
— Jillian Meredith (@LucidPolkadots) September 22, 2026
Novo Nordisk has pushed back on the growing number of lawsuits, saying its own internal safety studies found no increased risk of vision loss tied to its drugs. The company’s position highlights a real tension in this story. Millions of Americans now take GLP-1 drugs for diabetes and weight loss, and even a very small risk, spread across that many patients, can produce a real number of serious cases and a real wave of lawsuits.
Why This Story Matters To Everyday Patients
For patients and families weighing these drugs against their benefits, the practical takeaway isn’t panic, it’s informed caution. Anyone noticing sudden vision changes while on a GLP-1 medication should get to an eye doctor immediately rather than waiting to see if it passes. Gillen’s case, and the lawsuits stacking up behind it, are a reminder that new blockbuster drugs deserve the same scrutiny and honest labeling that older medications had to earn the hard way.
Regulators overseas have already acted on the caution side. The European Medicines Agency added vision-related warnings to GLP-1 drug labels, even as United States reporting notes the evidence for a clear causal link remains inconsistent. That split approach, warn now versus wait for more data, is likely to keep this story in headlines long after any single lawsuit reaches a verdict.
Sources:
youtube.com, boston25news.com, yahoo.com
